Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study

@inproceedings{Halpern2017MitoxantroneEA,
  title={Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study},
  author={Anna B. Halpern and Megan K. D. Othus and Emily M Huebner and Sarah A Buckley and Era L. Pogosova-Agadjanyan and Kaysey F Orlowski and Bart L Scott and Pamela S Becker and Paul C. Hendrie and T. L. Chen and M-E M Percival and Elihu Estey and Derek L. Stirewalt and Roland B Walter},
  booktitle={Leukemia},
  year={2017}
}
DNA methyltransferase inhibitors sensitize leukemia cells to chemotherapeutics. We therefore conducted a phase 1/2 study of mitoxantrone, etoposide and cytarabine following ‘priming’ with 5–10 days of decitabine (dec/MEC) in 52 adults (median age 55 (range: 19–72) years) with relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasms. During dose escalation in cohorts of 6–12 patients, all dose levels were well tolerated. As response rates appeared similar with 7 and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…